...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cellular Physiology >Novel nanohydrogel of hyaluronic acid loaded with quercetin alone and in combination with temozolomide as new therapeutic tool, CD44 targeted based, of glioblastoma multiforme
【24h】

Novel nanohydrogel of hyaluronic acid loaded with quercetin alone and in combination with temozolomide as new therapeutic tool, CD44 targeted based, of glioblastoma multiforme

机译：透明质酸的小说nanohydrogel加载槲皮素,结合temozolomide作为新的治疗工具,CD44有针对性的基础,多形性成胶质细胞瘤

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Glioblastoma multiforme is the most common and aggressive primary brain cancer with only ～3% of patients surviving more than 3 years from diagnosis. Several mechanisms are involved in drug and radiation resistance to anticancer treatments and among them one of the most important factors is the tumor microenvironment status, characterized by cancer cell hypersecretion of interleukins and cytokines. The aim of our research was the synthesis of a nanocarrier of quercetin combined with temozolomide, to enhance the specificity and efficacy of this anticancer drug commonly used in glioblastoma treatment. The nanohydrogel increased the internalization and cytotoxicity of quercetin in human glioblastoma cells and, when co‐delivered with temozolomide, contribute to an improved anticancer effect. The nanohydrogel loaded with quercetin had the ability to recognize CD44 receptor, a brain cancer cell marker, through an energy and caveolae dependent mechanism of internalization. Moreover, nanohydrogel of quercetin was able to reduce significantly IL‐8, IL‐6, and VEGF production in pro‐inflammatory conditions with interesting implications on the mechanism of glioblastoma cells drug resistance. In summary, novel CD44 targeted polymeric based nanocarriers appear to be proficient in mediating site‐specific delivery of quercetin via CD44 receptor in glioblastoma cells. This targeted therapy lead to an improved therapeutic efficacy of temozolomide by modulating the brain tumor microenvironment.
机译：多形性成胶质细胞瘤是最常见的积极的主要脑癌只有~ 3%病人存活3年以上诊断抗癌药物和辐射电阻治疗和其中的一个最重要的因素是肿瘤微环境地位,癌细胞的特征白细胞介素和细胞因子的分泌过多。我们的研究的目的是合成的nanocarrier槲皮素结合temozolomide,提高特异性和疗效的抗癌药物中常用胶质母细胞瘤的治疗。增加的内化和细胞毒性槲皮素在人类胶质母细胞瘤细胞,当公司交付与temozolomide,为一个提高抗癌效果。富含槲皮素的能力识别受体CD44,脑癌细胞标记,通过能源和小窝依赖的内化机制。nanohydrogel槲皮素能够减少明显IL 8,应承担的地理IL 6和VEGF在生产箴炎症条件与有趣影响胶质母细胞瘤的机制细胞耐药。有针对性的人们似乎为基础的聚合物精通调停地理位置特定的交付槲皮素的受体CD44在胶质母细胞瘤细胞。temozolomide的治疗效果调节大脑肿瘤微环境。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号